View Item 

Show simple item record

Meta‐analysis: oral anti‐viral agents in adults with decompensated hepatitis B virus cirrhosis
dc.contributor.authorSingal, A. K.en_US
dc.contributor.authorFontana, Robert Johnen_US
dc.date.accessioned2012-03-16T15:56:36Z
dc.date.available2013-05-01T17:24:42Zen_US
dc.date.issued2012-03en_US
dc.identifier.citationSingal, A. K.; Fontana, R. J. (2012). "Meta‐analysis: oral anti‐viral agents in adults with decompensated hepatitis B virus cirrhosis." Alimentary Pharmacology & Therapeutics 35(6): 674-689. <http://hdl.handle.net/2027.42/90203>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90203
dc.publisherWiley Periodicals, Inc.en_US
dc.titleMeta‐analysis: oral anti‐viral agents in adults with decompensated hepatitis B virus cirrhosisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid22257108en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90203/1/apt4990.pdf
dc.identifier.doi10.1111/j.1365-2036.2011.04990.xen_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceHadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long‐term therapy with adefovir dipivoxil for HBeAg‐negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743 – 51.en_US
dc.identifier.citedreferenceHadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen‐negative chronic hepatitis B. N Engl J Med 2003; 348: 800 – 7.en_US
dc.identifier.citedreferenceKamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end‐stage liver disease. Hepatology 2001; 33: 464 – 70.en_US
dc.identifier.citedreferenceWoo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta‐analyses. Gastroenterology 2010; 139: 1218 – 29.en_US
dc.identifier.citedreferenceTenney DJ, Rose RE, Baldick CJ, et al. Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503 – 14.en_US
dc.identifier.citedreferenceFleischer RD, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 2009; 51: 787 – 91.en_US
dc.identifier.citedreferencevan Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection. Hepatology 2004; 40: 1421 – 5.en_US
dc.identifier.citedreferenceBerg T, Marcellin P, Zoulim F, et al. Tenofovir is effective alone or with emtricitabine in adefovir‐treated patients with chronic‐hepatitis B virus infection. Gastroenterology 2010; 139: 1207 – 17.en_US
dc.identifier.citedreferenceRaijnders JG, Vries‐Sluijs T, Hansen BE, et al. Five‐year tenofovir therapy is asssociated with maintained virologic response but significant decline in renal function in HIV‐HBV coinfected patients. Hepatology 2009; 50: 506A.en_US
dc.identifier.citedreferenceRodriguez ‐Novoa S, Alvarez E, Labarga P, et al. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010; 9: 545 – 59.en_US
dc.identifier.citedreferenceFontana RJ. Side effects of long‐term oral antiviral therapy for hepatitis B. Hepatology 2009; 49: S185 – 95.en_US
dc.identifier.citedreferenceFontana RJ. Entecavir in decompensated HBV cirrhosis: the future is looking brighter. J Hepatol 2010; 52: 147 – 9.en_US
dc.identifier.citedreferenceLange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001 – 6.en_US
dc.identifier.citedreferenceSchiff E, Simsek H, Lee WM, et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008; 103: 2776 – 83.en_US
dc.identifier.citedreferenceBoxer AP, Protano MA, Vachon MC, et al. Telbivudine elevations of CPK in chronic hepatitis B patients in a clinical setting. Hepatology 2010; 52: 533A.en_US
dc.identifier.citedreferenceLavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97 – 107.en_US
dc.identifier.citedreferenceChu CM, Liaw YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 2009; 104: 1693 – 9.en_US
dc.identifier.citedreferenceBelongia EA, Costa J, Gareen IF, et al. NIH consensus development statement on management of hepatitis B. NIH Consens State Sci Statements 2008; 25: 1 – 29.en_US
dc.identifier.citedreferencede Jongh FE, Janssen HL, de Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigen‐positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630 – 5.en_US
dc.identifier.citedreferenceLiaw YF, Leung N, Kao JH, et al. Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263 – 83.en_US
dc.identifier.citedreferenceLok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661 – 2.en_US
dc.identifier.citedreferenceLiaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521 – 31.en_US
dc.identifier.citedreferenceLiaw YF, Sung JY, Chow CC, et al. Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double‐blind placebo‐controlled clinical trial. Hepatology 2003; 38 (Suppl. S4): 262A.en_US
dc.identifier.citedreferencePerrillo R, Tamburro C, Regenstein F, et al. Low‐dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109: 908 – 16.en_US
dc.identifier.citedreferenceJadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1 – 12.en_US
dc.identifier.citedreferencevon Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344 – 9.en_US
dc.identifier.citedreferenceVilleneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207 – 10.en_US
dc.identifier.citedreferenceYao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33: 301 – 7.en_US
dc.identifier.citedreferencePerrillo RP, Wright T, Rakela J, et al. A multicenter United States‐Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 424 – 32.en_US
dc.identifier.citedreferenceFontana RJ, Keeffe EB, Carey W, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002; 8: 433 – 9.en_US
dc.identifier.citedreferenceAndreone P, Biselli M, Gramenzi A, et al. Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation. Transplantation 2002; 74: 1119 – 24.en_US
dc.identifier.citedreferenceHann HW, Fontana RJ, Wright T, et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus‐related cirrhosis. Liver Transpl 2003; 9: 49 – 56.en_US
dc.identifier.citedreferenceManolakopoulos S, Karatapanis S, Elefsiniotis J, et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 2004; 99: 57 – 63.en_US
dc.identifier.citedreferenceNikolaidis N, Vassiliadis T, Giouleme O, et al. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti‐HBe positive/HBeAg‐negative chronic hepatitis B. Clin Transplant 2005; 19: 321 – 6.en_US
dc.identifier.citedreferenceTseng P, Lu SN, Tung HD, et al. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus‐related decompensated liver cirrhosis. J Viral Hepat 2005; 12: 386 – 92.en_US
dc.identifier.citedreferenceWong SN, Reddy KR, Keeffe EB, et al. Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl 2007; 13: 334 – 42.en_US
dc.identifier.citedreferenceOsborn MK, Han SH, Regev A, et al. Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol 2007; 5: 1454 – 61.en_US
dc.identifier.citedreferenceNishida T, Kobashi H, Fujioka S, et al. A prospective and comparative cohort study on efficacy and drug resistance during long‐term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. J Gastroenterol Hepatol 2008; 23: 794 – 803.en_US
dc.identifier.citedreferenceKao JTPC, Lai HC, Chuang PH, et al. Efficcay of entecavir in naive patients with chronic hepatitis B and decompensated liver cirrhosis. J Gastrotroenterol Hepatol 2009; 24: A202.en_US
dc.identifier.citedreferenceGane EC, Chan HL, Choudhuri G, et al. Treatment of decompensated HBV‐cirrhosis: results from 2‐years randomized trial with telbivudine or lamivudine. J Hepatol 2010; 52: S1 – 21.en_US
dc.identifier.citedreferenceKim KM, Choi WB, Lim YS, et al. Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine‐resistant hepatitis B virus. J Korean Med Sci 2005; 20: 821 – 8.en_US
dc.identifier.citedreferenceLiaw YF, Lee CM, Chien RN, et al. Switching to adefovir monotherapy after emergence of lamivudine‐resistant mutations in patients with liver cirrhosis. J Viral Hepat 2006; 13: 250 – 5.en_US
dc.identifier.citedreferenceSchiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait‐listed and post‐liver transplantation patients with lamivudine‐resistant hepatitis B: final long‐term results. Liver Transpl 2007; 13: 349 – 60.en_US
dc.identifier.citedreferenceZoulim F, Parvaz P, Marcellin P, et al. Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. Liver Int 2009; 29: 420 – 6.en_US
dc.identifier.citedreferenceLiaw YS, Raptopoulou‐Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: randomized, open‐label study. Hepatology 2011a; 54: 91 – 100.en_US
dc.identifier.citedreferenceLiaw YS, Sheen IS, Lee CM, et al. Tenofovir disproxil fumarate (TDF), emtricitabine/TDF and entecavir in the treatment of chronic hepatitis B subjects with decompensated liver disease. Hepatology 2011b; 53: 62 – 72.en_US
dc.identifier.citedreferencePellicelli AM, Barbarini G, Romano M, et al. Entecavir therapy for lamivudine resistant HBV cirrhotic patients waiting for OLT: viral and biochemical outcomes at one year. Hepatology 2009; 50: 514A.en_US
dc.identifier.citedreferenceShim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment‐naive patients with hepatitis B virus‐related decompensated cirrhosis. J Hepatol 2010; 52: 176 – 82.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt4990.pdf
Size:
244.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.